Australia markets open in 4 hours 20 minutes

QURE Jan 2023 22.500 put

OPR - OPR Delayed price. Currency in USD
Add to watchlist
1.2500+0.0300 (+2.46%)
As of 12:54PM EST. Market open.
Full screen
Previous close1.2200
Open1.2500
Bid1.0000
Ask1.6000
Strike22.50
Expiry date2023-01-20
Day's range1.2500 - 1.2500
Contract rangeN/A
Volume150
Open interest518
  • GlobeNewswire

    uniQure Highlights Therapeutic Potential of AMT-260 in Refractory Temporal Lobe Epilepsy (rTLE) at Virtual Research & Development Event

    ~ IND Submission and Clinical Development Expected to Begin in 2023 ~ ~ Advancements in Manufacturing and Technology Platform Also Highlighted ~ LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Nov. 29, 2022 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, hosted a virtual investor event focused on AMT-260, an AAV gene therapy for refractory temporal lobe epilepsy (rTLE) and other focal epil

  • Motley Fool

    Why Shares of uniQure Rose 14.61% on Wednesday

    Shares of uniQure (NASDAQ: QURE) climbed 14.61% on Wednesday. The stock jumped after the Food and Drug Administration (FDA), on Tuesday, approved Hemgenix (etranacogene dezaparvovec-drlb), a one-time gene therapy for hemophilia B. It was developed by uniQure, but CSL will commercialize the therapy. Hemophilia B, also known as Christmas disease, is rare.

  • Zacks

    uniQure (QURE) Partner Gets FDA Nod for Hemophilia B Gene Therapy

    uniQure (QURE) shares rise after its partner CSL Limited received FDA nod for one-time gene therapy, Hemgenix, for treating adults with Hemophilia B.